Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

Tubulis Closes €60 Million Series…

Cellaïon announces update to its Board of Directors: Dr. Fouzia LAGHRISSI-THODE joins the biotech as Member of the Board

Cellaïon announces update to its…

Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain

Confo Therapeutics Doses First Subjects…

Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity

– Initiated Enrollment in Phase…

TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients

TargED Biopharmaceuticals raises EUR 39…

eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement

Partnership Press Release eTheRNA Announces…

Epics Therapeutics Initiates First-in-Human Studies with EP282, an oral Investigational Drug for the treatment of gastrointestinal inflammatory disorders and cancer.

January 12th, 2022 – Epics…

Confo Therapeutics Expands Patent Estate for ConfoBody®-based GPCR Screening Platform

Confo Therapeutics Expands Patent Estate…

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

- Unblinded Data Established a…

Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer

NEW YORK, Dec. 9, 2021…